After the Ministry of Health and Welfare revealed its plan to lower the price of generics step by step at the 2022 NA Audit, the domestic pharmaceutical industry has been expressly expressing their displeasure on how pro-government the regulation is and criticized how the plan does not consider the realities of the industry.

The industry relayed its concerns on how the MOHW had opted to save NHI finances by regulating the price of generics rather than protecting the domestic industry, even though the sales of generics are a major means for profit generation used by domestic pharmaceutical companies to invest in R&D of new drugs.

Also, suggestions that policies to preserve drug